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Effects of Src kinase inhibition induced by dasatinib in
non–small cell lung cancer cell lines treated with cisplatin
Paolo Ceppi, Mauro Papotti, Valentina Monica,
Marco Lo Iacono, Silvia Saviozzi, Marisa Pautasso,
Silvia Novello, Stefano Mussino, Enrico Bracco,
Marco Volante, and Giorgio V. Scagliotti
University of Turin, Department of Clinical and Biological
Sciences, San Luigi Hospital, Orbassano, Italy
Abstract
c-Src is a tyrosine kinase involved in tumor proliferation,
migration, and angiogenesis and has been shown to
modulate the cytotoxicity following cisplatin-induced
DNA damages. c-Src is frequently activated in non–
small cell lung cancer (NSCLC) tissues and cell lines,
but no preclinical data regarding the effects of the novel
potent Src inhibitor, dasatinib (BMS-354825), in the
modulation of cisplatin resistance are currently available.
The present study reports that treatment with dasatinib
completely abrogated Src phosphorylation in the majority
of the NSCLC cell lines tested (n = 7), with modest ef-
fects on cell proliferation and survival. In five cell lines, a
higher cytotoxicity was observed delivering cisplatin in
combination with dasatinib: the most evident effects
were found in the squamous H520 cells due to the
effective block of cisplatin-induced Src phosphorylation.
Moreover, dasatinib treatment significantly blocked cis-
platin-induced transcription of a panel of DNA repair
and synthesis genes. In addition, a real-time PCR analy-
sis done on tumor and matched normal lung specimens
from 44 surgically resected NSCLC patients showed that
Src transcripts are significantly upregulated in 23% of
cases. In conclusion, Src-directed therapeutic strategies
could interfere with cisplatin resistance, possibly allow-
ing to reduce cisplatin doses, thus improving its efficacy.
The data of this study support further clinical studies aimed
to evaluate the efficacy of Src-inhibiting agents in combina-
tion with cisplatin in the treatment of NSCLC. [Mol Cancer
Ther 2009;8(11):3066–74]
Introduction
For the systemic treatment of non–small cell lung cancer
(NSCLC), platinum compounds represent the backbone of
commonly used cytotoxic combination with or without tar-
geted therapies. Platinum-based chemotherapy improves
survival in any stage of NSCLC, with the exclusion of stage
I, but its effect is limited and the choice of treatment in each
patient is highly influenced by the trade off between thera-
peutic activity and toxicity (1, 2).
Src (pp60c-Src) is a tyrosine kinase involved in multiple
fields of tumorigenesis including proliferation, migration,
and angiogenesis, recently indicated as a promising thera-
peutic target in the treatment of solid tumors (3, 4). Src ki-
nase is expressed and frequently activated in NSCLC
especially in active smoker males with squamous cell carci-
noma of the lung (5, 6). Retrospective studies in colon (7)
and breast (8) cancers clearly indicated an association between
Src activity and poor clinical prognosis. A previous study has
shown that survival of cancer cell lines to cisplatin-induced
DNA damages was mediated by the epidermal growth fac-
tor receptor (EGFR) pathway through the activation of Src
kinase (9). Moreover, in adenocarcinoma cells, ectopic over-
expression of oncogenic Src confers resistance to chemother-
apeutic agents by altering the expression levels of genes
involved in DNA repair pathways (10). Dasatinib (BMS-
354825; Bristol Myers Squibb) is a potent inhibitor of Src
kinase activity and has been recently approved for the use
of chronic myelogenous and Philadelphia chromosome–
positive acute lymphoblastic leukemia in patients resistant
or intolerant to imatinib (11, 12). Dasatinib has shown prom-
ising results in preclinical studies conducted in solid tumors
(13–16); in NSCLC, its in vitro efficacy has been recently
selectively related to the presence of activating mutations
of the EGFR (17). However, in the clinical practice, only a
minority of NSCLC harbor EGFR mutations, and for these
patients, a front-line treatment with EGFR tyrosine kinase-
inhibiting agents may be considered (18), whereas, for the
overwhelming majority of the NSCLC patients, platinum-
based chemotherapy remains the treatment of choice.
Because both Src and EGFR are activated and overex-
pressed in lung cancer cell lines and tissues independently
of the EGFR mutational status (6, 19), the aim of the present
study was to test the effect of dasatinib in modulating the
sensitivity to cisplatin in a panel of seven cell lines (all car-
rying wild-type EGFR) in terms of cell proliferation, apopto-
sis, and transcriptional regulation of a panel of DNA repair
genes associated to cisplatin resistance. In addition, the level
of Src expression was quantified by means of quantitative
real-time PCR in a consecutive series of resected NSCLC
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and in the corresponding normal lung tissues to determine
potential deregulation of Src mRNA transcript and its asso-
ciation with clinicopathologic characteristics.
Materials and Methods
Cell Lines, Cultures, and Drugs
Seven human NSCLC cell lines (three squamous cell car-
cinomas: Calu-1, H520, and SK-MES-1; one adenosqua-
mous: H596; two adenocarcinomas: H522 and H1395; and
one large-cell carcinoma: H1299) were purchased from the
American Type Culture Collection. All cell lines carried
wild-type EGFR. Cells were maintained in RPMI 1640
supplemented with 10% FCS, 2 mmol/L L-glutamine, pen-
icillin (25 units/mL), and streptomycin (25 μg/mL; all from
Sigma-Aldrich) in a humidified atmosphere containing
5% CO2 at 37°C.
Dasatinib and imatinib mesylate (STI-571; Novartis) were
prepared as 20 mmol/L and dissolved in DMSO (Sigma-
Aldrich). Dasatinib was used in all experimental settings at
a dose of 100 nmol/L, as reported previously (16), and the
concentration of DMSO used to deliver dasatinib had no
effect on cell proliferation (data not shown). Original stock
solutions of cisplatin (cis-diammine-dichloroplatinum;
Pfizer) at a concentration of 0.5 mg/mL were stored at
4°C and freshly dissolved in culture medium before use.
Cell Viability Assay
Cells were plated in 96-well plates for 24 h and then
treated with increasing concentrations of cisplatin (range,
1-50 μmol/L) for 48 h in the presence or absence of dasa-
tinib 100 nmol/L. A MTT (Sigma-Aldrich) assay was done
according to the manufacturer's instructions. Absorbance
was measured at 590 nm with a microplate reader.
Apoptosis Assay
Cells were seeded in 6-well plates at appropriate density
and then treated for 48 h with 5, 10, or 20 μmol/L cisplatin
in the presence or absence of 100 nmol/L dasatinib. Cells
were then harvested and stained with Annexin V and pro-
pidium iodide and then analyzed on a cytofluorimeter by
FACScan (BD Biosciences). Propidium iodide–positive cells
were considered as necrotic, Annexin V–positive/propi-
dium iodide–negative as apoptotic cells, and the double-
negative cells as alive. All untreated controls ranged from
5% to 10% of apoptotic cells. Results are expressed as ratios
between the percentage of apoptotic/nonapoptotic cells.
Western Immunoblot Analysis
After treatments, cells were lysed in 50 mmol/L Tris-HCl
(pH 7.5), 150 mmol/L NaCl, 0.5% NP-40, 10 mmol/L glyc-
erol, 5 mmol/L EDTA, and 0.5% sodium deoxycholate and
the lysates were treated with a mixture of protease and ty-
rosine phosphatase inhibitors (1 mmol/L phenylmethylsul-
fonyl fluoride, 1 μg/mL aprotinin, 1 μg/mL leupeptin, and
1 mmol/L sodium orthovanadate). Proteins were separated
on 8% SDS-PAGE and blotted onto polyvinylidene fluoride
membrane (Hybond-P; Amersham). Filters were incubated
with the following monoclonal antibodies against β-actin
(Santa Cruz Biotechnology), pan-Src, and phosphoY416-Src
(Cell Signaling). Detection was done using enhanced chemi-
luminescence kit (Pierce).
Figure 1. Whole-cell lysates ob-
tained from all cell lines were subjected
to Western blot analysis with (A) pan-
Src (total Src) antibody and (B) phos-
phoY416-Src antibody in the presence
(+) or absence (−) of 100 nmol/L dasa-
tinib for 24 h. β-Actin antibody was
used as a loading control. C, cell prolif-
eration assay in NSCLC cell lines in re-
sponse to 100 nmol/L dasatinib (DAS)
for 48 h. Bars, SD of at least eight re-
plicates. Asterisk, significant difference
of treated compared with untreated
controls (NT).
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RNA Isolation and cDNA Synthesis from Cells and
Fresh Snap-Frozen NSCLC Specimens
Total RNA was isolated from lung specimens using the
RNeasy 96 kit implemented on Biorobot 8000 (Qiagen) ac-
cording to the manufacturer's instructions. RNA was ex-
tracted and retrotranscribed to cDNA as described
previously (20). Total RNAwas isolated from cell lines with
Qiazol lysis reagent (Qiagen) according to the manufac-
turer's instructions.
Quantitative Real-time PCR
Relative cDNA quantitation for each gene was done by a
fluorescence-based real-time detection method (ABI PRISM
HT7900; Applied Biosystems). The sequences of the primers
and probes used for excision repair cross-complementing 1
(ERCC1), ribonucleotide reductase subunit M1 (RRM1), to-
poisomerase IIα (TopoII-α), thymidylate synthase (TS), poly-
merase η (Pol η), and β-actin (reference gene) have been
published previously (20–22). E2F transcription factor 1
(E2F1) primers and probe were designed according to the
Ref. Seq. NM_005225 and sequences were as follows: forward
5′-CTCCAAGCCGTGGACTCTT-3′, reverse 5′-ACATC-
GATCGGGCCTTGT-3′, and probe 5′-CGGAGAACTTTCA-
GATCTCCCTTAAGAGCA-3′. Src primers and probe were
designed according to the Ref. Seq. NM_005417 and se-
quences were forward 5′-CCTCGTGCGAGAAAGTGAG-3′,
reverse 5′-TGGCGTTGTCGAAGTCAG-3′, and probe 5′-
CCACGAAAGGTGCCTACTGCCTCTC-3′. All primers and
probeswere intron-spanning to avoid genomicDNA contam-
ination and validation process was done as described previ-
ously (23). Primers and probe for breast cancer 1 (BRCA1)
gene were purchased as “Assay-on-Demand” (Applied Bio-
systems). PCR mixture and cycling conditions were as de-
scribed previously (20).
Patients and Samples
Fresh snap-frozen surgical specimens of both tumor
and corresponding normal lung tissues of 44 NSCLC pa-
tients completely resected between 2003 and 2004 at the
San Luigi Hospital were consecutively collected. Patients'
characteristics were as follows: median age of 63 years
(range, 41-82), 86% were male, 15 had squamous cell car-
cinoma, 28 adenocarcinoma, and 1 large cell carcinoma,
84% had postsurgical stage I or II, and median survival
of 56 months, with a minimum follow-up time of 4 years.
None of the patients received preoperative or postopera-
tive treatments with chemotherapy and/or radiotherapy
mainly based on the negative outcomes of a large phase
III study done at that time in Europe (24). All cases were
reviewed and classified according to the WHO classifica-
tion by one of the investigators (M.P.). All patients carried
wild-type EGFR gene as reported previously (19). The
study was approved by the institutional review board
of our University Hospital.
Figure 2. Evaluation of cell viability
after combined drug treatment
measured by MTT assay. Increasing
dose of cisplatin (CDDP) alone (con-
tinuous line) or in combination with
100 nmol/L dasatinib (dashed line)
was administered in NSCLC cell
lines for 48 h. Bars, SD values of
at least eight replicates of MTT
measurements.
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Statistical Analyses
In cell line experiments, to assess the drug effects on cell
proliferation, the t test was done using the GraphPad
software 5.0. In Western blot experiments, integrated
densitometry data were obtained by the ImageJ software.
In the transcriptional regulation assay, ΔCt values and SDs
were calculated according to User's Bulletin #2 (Applied
Biosystems). To test differential Src mRNA expression
between tumors and corresponding normal tissues, the
ΔΔCt method was used and significant overexpression
was defined when 2−ΔΔCt values were >2. Relative Src
levels in tumors and normal lung tissues were estimated
with the ΔCt method and normalized by subtracting all
ΔCt values by the highest and converted in a linear scale.
To test differential Src expression in the overall population
of tumor versus normal lung and to test significant associa-
tions with clinicopathologic variables, the Mann-Whitney
U and Kruskal-Wallis tests were used. Univariate analy-
sis of survival was done with the Kaplan-Meier method
dividing patients according to different cutoffs of Src
levels, and the significance was estimated with the
log-rank test. The correlation between the level of Src
upregulation and transcript expression in tumor samples
was tested by Spearman's correlation test. Statistical
significance was set at P = 0.05.
Results
Dasatinib Treatment Impairs Src Activity with
Modest Effects on the Growth of NSCLC Cell Lines
The total amount of Src kinase (c-Src) protein in the cell
lines was quantified by Western blot analysis. As shown in
Fig. 1A, basal Src protein levels were slightly different:
H522, Calu-1, and H1395 had the lowest and H520 and
SK-MES-1 had the highest expression levels, respectively.
In quantitative real-time PCR experiments, the amount of
Src transcript was not significantly associated with protein
levels, although a trend toward significance was observed
(P = 0.08; data not shown).
Src kinase was found phosphorylated (at Y416) in all cell
lines (Fig. 1B). The effect of dasatinib in the inhibition of Src
activity and the consequent cell growth block was tested.
The exposure to 100 nmol/L dasatinib for 48 h produced
a decrease of its phosphorylation level >80% in the majority
of the cells (H1395, SK-MES-1, Calu-1, and H520), of 75% in
H596 and 52% and 44% in H1299 and H522, respectively (all
densitometric data). After treatment, the growth of 4 of 7 cell
lines was significantly inhibited (Fig. 1C). The extent of
growth inhibition was not significantly associated with Src
basal expression (at both mRNA and protein levels) nor to
its phosphorylation level. In addition, 24 and 48 h treatment
with dasatinib did not modify Src transcript and protein
levels (data not shown).
Dasatinib Enhances Cisplatin-Induced Cytotoxicity
The effect of the concomitant administration of dasatinib
and cisplatin in the cell lines was evaluated by means of cell
viability and apoptosis assays after 48 h of treatment. The
results of MTT assays showed that the majority of cell lines
(5 of 7) had an enhanced sensitivity to cisplatin in the pres-
ence of dasatinib at a dose of 100 nmol/L, whereas little and
no differences were observed in H596 and H522 cell lines,
respectively (Fig. 2). The observed effects were not related
to basal cell sensitivity to cisplatin or dasatinib, and no
Figure 3. Evaluation of apoptosis
rate measured by Annexin V/propi-
dium iodide staining. NSCLC cell lines
were treated for 48 h with cisplatin,
dasatinib, and cisplatin/dasatinib com-
bination. Cisplatin concentrations were
5 μmol/L for H596, 10 μmol/L for Calu-
1, H520, and H522, and 30 μmol/L for
H1299. Asterisk, significantly higher
apoptotic rate in dasatinib/cisplatin-
treated cells compared with those trea-
ted with cisplatin alone.
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changes were observed when different schedules of drug
combinations (simultaneous or subsequent) were tested
(data not shown).
Furthermore, although dasatinib showed modest proa-
poptotic effects when administered as a single agent (the
highest effect was observed in H596 cells), a higher rate
of apoptotic cells was found with the exposition to the
dasatinib/cisplatin combination compared with that ob-
served with cisplatin alone (Fig. 3). The two squamous
carcinoma lines Calu-1 and H520 (Figs. 3 and 4A, respec-
tively) showed significantly stronger responses when the
drugs were delivered in combination. Similar to cytotoxi-
city assays, this effect was not detected in the H522.
Figure 4A shows light microscopy pictures of the H520
cells in different conditions: both dasatinib and cisplatin,
administered at 100 nmol/L and 10 μmol/L doses, re-
spectively, were unable to affect either survival or alter
cell morphology, but a strong cytotoxic effect was ob-
served when the two drugs were concomitantly added:
the cells rounded-up, losing their original shapes, and
as a consequence, their adhesion (either cell-cell or cell-
plate) properties were impaired. The cisplatin-induced cell
death at 10 μmol/L dose in the presence of dasatinib was
found comparable with that induced by cisplatin alone at
20 μmol/L dose (data not shown). The status of Src phos-
phorylation was evaluated under these experimental con-
ditions. Figure 4B shows that H520 cells undergo an
increase in Src phosphorylation levels after cisplatin expo-
sure at 10 μmol/L. Such increase was quantified with in-
tegrated densitometry (as the ratio of phosphoY416-Src/
pan-Src; Fig. 4B, bottom) as 42% compared with untreated
cells. A 70% increase in Src phosphorylation was ob-
served after the treatment with 20 μmol/L, but this con-
centration was already highly cytotoxic to observe
differences with combined treatments. Src phosphoryla-
tion, both endogenous and induced by cisplatin, was
found impaired by dasatinib treatment (Fig. 4B).
To confirm the specificity of Src inhibition in the observed
effects, H520 cells were treated in parallel with imatinibmesy-
late. Imatinib is a drug that, similar to dasatinib, targets Bcr/
Abl, c-kit, and platelet-derived growth factor receptor but has
a lower inhibiting activity on Src family kinases. Indeed, scant
effects on Src inhibition, cell growth, and cisplatin-induced
death were observed at concentration up to 5 μmol/L after
24 to 48 h of treatment (Supplementary Fig. S1).
Finally, a sequence analysis of the dasatinib-binding sites
in Src gene done in H520 and H522 cells revealed no differ-
ences in terms of nucleotide sequence (data not shown).
Dasat in ib Inhib i ts Cisp lat in - Induced mRNA
Transcription of DNA Repair and Synthesis Genes
The effect of dasatinib alone or in combination with cis-
platin on the expression of gene potentially involved in the
resistance to cisplatin was investigated by means of quanti-
tative real-time PCR in all cell lines. A panel of seven genes
belonging to DNA repair and synthesis pathways was se-
lected, including ERCC1, TS, Pol η, BRCA1, TopoII-α,
RRM1, and E2F1. The results of the experiments indicated
that the transcript levels of many of these genes were upmo-
dulated by the cancer cells after cisplatin treatment for
24 h (Fig. 5). By contrast, the presence of dasatinib blocked
the cisplatin-induced mRNAs transcription. Again, this ef-
fect was evident at different levels of intensity in the differ-
ent cells tested, being more intense in H520, whereas only
minimal changes were observed in H522.
Src mRNA Is Frequently Upregulated in NSCLC
Specimens but Lacks Prognostic Effect
Src transcript expression was tested in NSCLC samples
and the corresponding normal lung tissues. The results
showed a significant upregulation of Src levels, being 2.55
(from 1.4 to 5.9) the median level in nonneoplastic lungs
Figure 4. A, effect of combined
dasatinib and cisplatin treatment in
lung squamous carcinoma cel l
H520. Cells were treated for 48 h at
the indicated concentration. Light mi-
croscopy pictures were taken at
×100 magnification. B, whole-cell ly-
sates of H520 treated for 24 h with
cisplatin, dasatinib, and cisplatin/da-
satinib combinations at the indicated
doses were immunoblotted with anti-
phospho-Src, pan-Src, and β-actin
(loading control). Bottom, histograms
show integrated densitometry data
representing phosphorylation levels
(phosphoY416-Src/pan-Src ratio).
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compared with 3.51 (from 1 to 9.2; all unit-less ratios) for the
tumor tissues (P = 0.03; Fig. 6A). The level of Src upregula-
tion (expressed as tumor/normal ratios) was significantly
correlated with the levels of expression in the tumors (RS =
0.76; P < 0.0001; Fig. 6B). In addition, by the analysis of
individual tumor/normal ratios adopting a cutoff value
>2-fold for Src upregulation, 10 of 44 (23%) patients had a
significant upregulation of Src, whereas, in 16 (36%) patients,
a ratio between 0.5 and 2 was found, and only 2 (4.5%)
patients had a ratio <0.5-fold, that is, significantly downre-
gulated (Fig. 6C). No correlation between Src relative levels
in tumoral tissues or between Src upregulation ratios and
patients' characteristics such as gender, age, histotype, tumor
size, lymph node status, clinical stage, and survival was
found (Supplementary Table S1).
Discussion
The present study shows that (a) Src inhibition by dasatinib
could be effective in tumor growth control of lung cancer
cells; (b) dasatinib can enhance cisplatin cytotoxicity, likely
impairing the cisplatin-induced modulation of DNA repair
and synthesis genes; and (c) a subset of NSCLC have an in-
creased Src kinase mRNA expression in tumors.
Src kinase is emerging as a potential critical target to be
preclinically investigated in NSCLC (3, 4) and the present
study tested the effects of Src inhibition by dasatinib in a
panel of NSCLC cell lines. Consistent with data reported
previously, treatment with dasatinib at a relatively low con-
centration impaired Src phosphorylation in the majority of
cell lines tested (Fig. 1B), showing a modest effect on cell
survival apparently not correlated with both Src basal level
and phosphorylation, similar to previous findings in differ-
ent lung cancer cell lines (17). Recent reports have related
the sensitivity to dasatinib with the presence of EGFR-
activating mutations (17), but no data on the combined
administration of dasatinib and cytotoxic agents were avail-
able. A higher cytotoxicity and/or apoptotic rate was ob-
served in all cell lines when cisplatin and dasatinib were
simultaneously administered, except for the H522 cells. This
unresponsiveness could be due to the residual Src activity
observed after dasatinib treatment, and the possible me-
chanisms of resistance involved are worth of further inves-
tigations. A preclinical study has recently indicated a
significant correlation between the level of inhibition of
Src phosphorylation by dasatinib in peripheral blood
mononuclear cells and that observed in tumors in a mouse
xenograft model (25), and this could represent a potential
strategy for the selection of the patients who may benefit
from the treatment. To investigate one of the possible me-
chanisms of the differential responsiveness, the nucleotide
sequences in the ATP-binding pocket of Src of the “respon-
sive” H520 and the “unresponsive” H522 cells were ana-
lyzed, but no difference was detected. In the H520 cells,
which showed remarkable cytotoxic effects when the two
drugs were delivered in combination (compared with con-
trols treated with cisplatin alone) in both viability and ap-
optosis assays, the effective block of cisplatin-induced Src
phosphorylation on catalytic site was shown. This is in line
with recent in vitro findings reporting that EGFR phosphor-
ylation following chemotherapy could determine the re-
sponse to combined gefitinib and chemotherapy treatment
(26). Altogether, these data contribute to highlight the me-
chanisms of the acquired resistance to cytotoxic drugs as
Figure 5. Effects of dasatinib on
cisplatin-induced mRNA transcription
of seven genes involved in DNA re-
pair and synthesis. Histograms repre-
sent ΔΔCt ± SD values of at least
three replicates.
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possible targets of the new class of anticancer agents (27)
and support future investigations addressed to test the cor-
relation between Src phosphorylation/activation levels and
tumor chemosensitivity.
Src kinase inhibition by means of RNA interference or
specific drugs has already been shown to enhance in vitro
toxicity of cancer cells to different agents (28, 29), and al-
though in the present article, for most of the responsive
cell lines, the effects of the cisplatin/dasatinib combina-
tions seemed to be additive rather than synergistic (Fig. 2),
further studies both in vitro and in vivo should be ad-
dressed to clarify the nature of the interaction between
these two drugs in NSCLC, similar to what recently re-
ported in colorectal cancer model (30). Dasatinib targets
other proteins with tyrosine kinase activity such as Bcr/
Abl, c-kit, and platelet-derived growth factor receptor
(12). Thus, to test the specificity of Src inhibition in the
phenomena observed in H520, all the experiments were
done in parallel with imatinib mesylate, a drug mainly
targeting Bcr/Abl that also inhibits c-kit and platelet-
derived growth factor receptor but with low efficacy on
Src family kinases (31). The results showed that imatinib
had minimal effects on Src inhibition and on cisplatin-
induced death inH520 even at relatively high concentrations
able to inhibit other kinases (16). Therefore, the effects of
dasatinib here presented seem specifically attributable to
the inhibition of Src family kinases, although the precise
family member involved remains to be determined.
c-Src kinase has been implicated in the resistance to var-
ious anticancer treatments in different in vitro experimental
settings (28, 29, 32) and the transfection of cancer cells with
v-Src showed to increase the repair of cisplatin-DNA inter-
strand cross-links (10). Similarly, the results of the present
study reported lower expression levels of a panel of genes
belonging to DNA repair pathways in dasatinib/cisplatin
compared with cells treated with cisplatin alone. Whether
this effect was due to the effective block of Src activity or
to the higher cytotoxicity of the combined treatment
remains unclear, but these findings are intriguing because
different retrospective studies have shown the mRNA
overexpression of these genes as strongly associated
with the resistance of NSCLC patients to platinum-based
chemotherapy (22, 33–35).
Additionally, the present study assessed the regulation of
Src mRNA transcripts in surgically resected NSCLC and in
the corresponding normal lung tissues. In 23% of cases, we
detected a significant upregulation of mRNA levels com-
pared with 4.5% of downregulated samples. Although these
data are based on the quantification of mRNA, they are con-
sistent with those reported previously about Src protein
quantification, which showed higher levels in tumors, as
well as a positive correlation with enzymatic activity (5).
However, neither the upregulation nor the overexpression
of Src in tumors had an effect on patients' survival. These
results agree with a study carried out on a large case-series
of NSCLC patients (n = 370), which evaluated the activity of
Src family kinase proteins using a phospho-specific anti-
body in paraffin-embedded tissues. In 33% of cases, Src ac-
tivation was detected, but no prognostic association was
detected (6). Although there is no effect of Src activity and
expression on NSCLC patients' survival, the identification
of a subgroup of patients with transcriptional upregulation
Figure 6. A, general upregulation of
Src transcript levels in 44 NSCLC fresh-
frozen surgical specimens compared
with the corresponding normal lung
tissues. P (Mann-Whitney U test). B, cor-
relation between the level of Src upregu-
lation expressed as tumor/normal ratios
and Src transcript levels in tumor sam-
ples. P (Spearman's rank correlation
test). C, individual ratios between Src
mRNA levels in tumor compared with
normal lung. Bars, SD of triplicate mea-
surements. Asterisk, cases with at least
2-fold Src transcript upregulation.
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of a kinase involved in many aspects of tumorigenesis and
linked to chemoresistance is worth of further consideration.
Future studies should be addressed to elucidate the mo-
lecular pathways leading to this aberrant transcription/
activation in NSCLC or should evaluate the prognostic effect
of Src expression levels/activity in patients treated with cyto-
toxic regimens. Moreover, both the increased activity and the
upregulation of its expression in tumors could be used as a
biomarker to drive the selection of patients to be treated with
Src-targeting agents. The results of a recent study focused on
the identification of lesions associated with therapeutically
relevant oncogenic pathways have clearly shown that the
cells with the amplification of dasatinib target genes were
more sensitive to the drug in both in vitro and in vivo settings
(36). Because the wide majority of NSCLC patients are diag-
noses in advanced, unresectable stages, and no adjacent
normal lung tissues could be used to measure the levels of
Src transcription, the high correlation between transcriptional
regulation and Src expression in tumors here reported
(Fig. 6B) could be useful for future clinical investigations
based on the sole assessment of tumor specimens.
In conclusion, the results of this study further support
the hypothesis of an integration of cytotoxic chemotherapy
with inhibitors of specific molecular pathways in the at-
tempt to ameliorate the outcomes of NSCLC patients.
Future studies evaluating the efficacy of Src-inhibiting
agents in combination with cisplatin are clearly warranted.
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